AU2010274125B2 - Methods of attenuating the loss of functional status - Google Patents

Methods of attenuating the loss of functional status Download PDF

Info

Publication number
AU2010274125B2
AU2010274125B2 AU2010274125A AU2010274125A AU2010274125B2 AU 2010274125 B2 AU2010274125 B2 AU 2010274125B2 AU 2010274125 A AU2010274125 A AU 2010274125A AU 2010274125 A AU2010274125 A AU 2010274125A AU 2010274125 B2 AU2010274125 B2 AU 2010274125B2
Authority
AU
Australia
Prior art keywords
bcaa
nutritional composition
vitamin
protein
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010274125A
Other languages
English (en)
Other versions
AU2010274125A1 (en
Inventor
Ingo Arne Jurk
Kevin Burke Miller
Zamzam Kabiry Roughead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2010274125A1 publication Critical patent/AU2010274125A1/en
Application granted granted Critical
Publication of AU2010274125B2 publication Critical patent/AU2010274125B2/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: NESTEC S.A.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
AU2010274125A 2009-07-20 2010-07-15 Methods of attenuating the loss of functional status Ceased AU2010274125B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22680609P 2009-07-20 2009-07-20
US61/226,806 2009-07-20
US33424710P 2010-05-13 2010-05-13
US61/334,247 2010-05-13
PCT/US2010/042083 WO2011011252A1 (en) 2009-07-20 2010-07-15 Methods of attenuating the loss of functional status

Publications (2)

Publication Number Publication Date
AU2010274125A1 AU2010274125A1 (en) 2012-02-16
AU2010274125B2 true AU2010274125B2 (en) 2015-11-05

Family

ID=42990259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010274125A Ceased AU2010274125B2 (en) 2009-07-20 2010-07-15 Methods of attenuating the loss of functional status

Country Status (13)

Country Link
US (1) US20120195873A1 (enExample)
EP (2) EP3231435A1 (enExample)
JP (1) JP2012533627A (enExample)
CN (1) CN102647990A (enExample)
AU (1) AU2010274125B2 (enExample)
BR (1) BR112012001488A2 (enExample)
CA (1) CA2768471A1 (enExample)
IN (1) IN2012DN00486A (enExample)
MX (1) MX2012000943A (enExample)
RU (1) RU2012105901A (enExample)
SG (1) SG177664A1 (enExample)
WO (1) WO2011011252A1 (enExample)
ZA (1) ZA201201229B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544555B1 (en) * 2010-03-12 2018-05-16 Nestec S.A. Compositions for masking the flavor of leucine and methods for making same
JP2013529193A (ja) * 2010-04-26 2013-07-18 ネステク ソシエテ アノニム 非経口栄養から経腸栄養へ離脱させるための栄養組成物及び方法
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
CN103370062A (zh) * 2011-02-25 2013-10-23 默克专利股份有限公司 增强关节和/或姿势稳定性的组合物
JP2014512372A (ja) * 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−ＨＩＣＡ及びエイコサペンタエン酸を含有する栄養組成物
BR112013031086A2 (pt) * 2011-06-08 2016-11-29 Nestec Sa composições nutricionais tendo componentes de membrana de glóbulo de gordura de leite exógenos
JP2013051920A (ja) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp 骨密度強化補助食品
EP2580967A1 (en) * 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
PL2583566T3 (pl) * 2011-10-21 2016-01-29 Nestec Sa Micele serwatkowego białka do zwiększania masy mięśni i sprawności
EP2583563A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
EP2583565A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
EP2800478A2 (en) * 2012-01-03 2014-11-12 Nestec S.A. Compositions and methods for the stability of reactive amino acids in a food matrix
RU2520036C2 (ru) * 2012-03-01 2014-06-20 Общество с ограниченной ответственностью "Институт новых технологий" Пищевой продукт "миоактив-спорт" для питания людей, подверженных интенсивным физическим нагрузкам
MX367861B (es) 2012-10-04 2019-09-09 Abbott Lab Una composición nutricional para usarse en la preservación del músculo esquelético.
CN103783532B (zh) * 2012-10-29 2016-06-08 杭州纽曲星生物科技有限公司 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法
CN103271350B (zh) * 2013-03-04 2014-09-24 中国航天员科研训练中心 空间站航天员太空高能压缩食品及其制法
WO2014152606A2 (en) 2013-03-14 2014-09-25 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
MX2015013000A (es) 2013-03-15 2015-12-01 Abbott Lab Metodos de mantenimiento y mejora de la funcion muscular.
EP2986156B2 (en) * 2013-04-15 2020-06-03 Société des Produits Nestlé S.A. Use of whey protein in combination with electrical muscle stimulation
HK1221609A1 (zh) * 2013-05-01 2017-06-09 Abbott Laboratories 增强老化肌肉再生的方法
US20140357576A1 (en) * 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
EP3021690B1 (en) 2013-06-10 2017-05-17 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
JP6279851B2 (ja) * 2013-07-19 2018-02-14 雪印メグミルク株式会社 筋萎縮防止及び／又は筋合成促進剤
US11478010B2 (en) * 2014-07-21 2022-10-25 Societe Des Produits Nestle S.A. Nutritional products to promote safe swallowing for individuals with dysphagia
NO3006027T3 (enExample) * 2014-10-08 2018-04-14
BR112017005762B1 (pt) * 2014-10-14 2021-10-05 Société des Produits Nestlé S.A. Composição compreendendo uma fonte de proteína, e um antioxidante e seu uso
TR201908045T4 (tr) * 2014-11-19 2019-06-21 Nestec Sa Peynir Altı Suyu Protein Miselleri Ve Pektin Karışımının Vücut Ağırlığını Kontrol Amaçlı Kullanımı.
EP3851114B1 (en) * 2015-11-20 2024-10-09 Société des Produits Nestlé S.A. Composition comprising micellar whey protein, vitamin d and calcium for use in decreasing fat deposition in skeletal muscle in an elderly individual
CN108430490A (zh) * 2015-12-03 2018-08-21 株式会社明治 营养组合物
ES3044632T3 (en) 2015-12-22 2025-11-27 Nestle Sa A non-therapeutic use of adenosylcobalamin for increasing muscular fiber size
JP6848962B2 (ja) * 2016-03-16 2021-03-24 味の素株式会社 行動体力向上剤
JP6948103B2 (ja) * 2016-04-14 2021-10-13 株式会社明治 フレイル改善用組み合わせ物
CA3020087A1 (en) * 2016-04-14 2017-10-19 Michael LUCEY Combinational compositions and methods of use thereof
EP3463321A1 (en) * 2016-05-27 2019-04-10 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
HRP20201141T1 (hr) * 2016-11-16 2020-10-30 Fresenius Kabi Deutschland Gmbh Nutritivna kompozicija za primjenu u terapiji pacijenata sa sarkopenijom i/ili slabošću ili pacijenta sa presarkopenijom i/ili pred-slabošću
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11504413B2 (en) 2017-03-03 2022-11-22 Exerkine Corporation Multi-nutrient composition
JP7198749B2 (ja) * 2017-06-01 2023-01-04 株式会社明治 栄養組成物
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP7044306B2 (ja) * 2018-07-31 2022-03-30 ユーハ味覚糖株式会社 ロイシン血中濃度上昇促進剤及びその用途
EP3893671A1 (en) * 2018-12-13 2021-10-20 Société des Produits Nestlé S.A. Liquid concentrates formulated for dilution into nutritional products to promote safe swallowing for individuals with dysphagia
HUE062802T2 (hu) 2019-06-28 2023-12-28 Dompe Farm Spa Elágazó láncú aminosavakat tartalmazó új készítmény
EP4049672A4 (en) * 2019-10-25 2023-11-29 Ajinomoto Co., Inc. Muscle quality improvement agent
CN121196172A (zh) * 2025-11-28 2025-12-26 云南农业大学 一种增肌膳食黄酮复合蛋白组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028211A1 (en) * 2005-09-09 2007-03-15 Murray Goulburn Co-Operative Co Limited Composition of whey growth factor extract for reducing muscle inflammation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2683492B2 (ja) * 1993-09-07 1997-11-26 雪印乳業株式会社 ミセル状ホエー蛋白質、その溶液、その粉末およびミセル状ホエー蛋白質の製造法
CN1101810A (zh) * 1994-08-23 1995-04-26 谢宝兴 茯苓枸杞子口服液饮料袋泡茶及其生产方法
EP1062876A1 (en) * 1999-02-25 2000-12-27 Societe Des Produits Nestle S.A. Caseinoglycomacropeptides as calcification agent
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
US7794770B2 (en) * 2004-10-07 2010-09-14 Next Proteins, Inc. Protein beverage and method of making the same
CA2537647A1 (en) * 2005-03-01 2006-09-01 Six Star Formulations Ltd. Supplemental dietary composition for supporting muscle growth, recovery and strength
FR2882896B1 (fr) * 2005-03-14 2007-05-04 Larena Sa Composition alimentaire pour prevenir le syndrome de fragilite chez les personnes agees
US20070020358A1 (en) * 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
DE602006019941D1 (de) * 2006-03-27 2011-03-17 Nestec Sa Im Proteingehalt angereichertes gefrorenes Dessert
ATE424733T1 (de) * 2006-03-27 2009-03-15 Nestec Sa Im produkt generierte molkenprotein-micellen
WO2008046870A1 (en) * 2006-10-19 2008-04-24 Nestec S.A. Long-term feed - cancer patient
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
MX2010012171A (es) * 2008-05-21 2010-11-30 Stokely Van Camp Inc Bebida de recupercion a base de leche.
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028211A1 (en) * 2005-09-09 2007-03-15 Murray Goulburn Co-Operative Co Limited Composition of whey growth factor extract for reducing muscle inflammation

Also Published As

Publication number Publication date
US20120195873A1 (en) 2012-08-02
BR112012001488A2 (pt) 2019-10-08
CN102647990A (zh) 2012-08-22
WO2011011252A1 (en) 2011-01-27
JP2012533627A (ja) 2012-12-27
RU2012105901A (ru) 2013-08-27
CA2768471A1 (en) 2011-01-27
SG177664A1 (en) 2012-02-28
EP2456448A1 (en) 2012-05-30
ZA201201229B (en) 2013-07-31
IN2012DN00486A (enExample) 2015-05-22
MX2012000943A (es) 2012-02-28
EP3231435A1 (en) 2017-10-18
AU2010274125A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US20120195873A1 (en) Methods of attenuating the loss of functional status
ES2832506T3 (es) Composiciones que comprenden ribósido de nicotinamida y una urolitina
JP7592632B2 (ja) カルシウムと、オレウロペイン又はその代謝産物のうちの少なくとも１つとの組み合わせを使用する組成物及び方法
ES2622116T3 (es) Composición nutricional para la estimulación de la síntesis de proteínas musculares
ES2994610T3 (en) Compositions comprising an urolithin compound
EP3021690B1 (en) Muscle preservation in overweight or obese adult during weight loss program
US20160303177A1 (en) Nutritional supplement
US20130018102A1 (en) Nutritional supplement for the enhancement of muscle performance and recovery
US20160303176A1 (en) Nutritional supplement
US20160095894A1 (en) Dietetic multi-component system
US20250302789A1 (en) Compositions comprising a combination of creatine and oleuropein or a metabolite thereof and their use for improving muscle function
Serafini et al. Nutritional approach to sarcopenia
EP3419613A1 (en) Compositions and methods for improving mitochondrial function
RU2836322C1 (ru) Биологически активная добавка к пище для улучшения скоростных и силовых показателей в спорте
US20210393559A1 (en) Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise
WO2025166466A1 (en) A method to treat body composition resistance
JP2025515695A (ja) カフェインとオレウロペイン又はその代謝産物との組み合わせを含む組成物、及び筋肉機能を改善するためのその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): NESTEC S.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired